| Literature DB >> 9090476 |
K Seetalarom1, A P Kudelka, C F Verschraegen, J J Kavanagh.
Abstract
Paclitaxel and docetaxel are active in the treatment of patients with advanced ovarian cancer. The taxanes in various dose schedules achieve response rates of 10-50% with a median overall survival of 10-12 months in patients with platinum-refractory disease. Paclitaxel has activity in chemotherapy-naive patients when administered alone or in combination with platinum. The role of intraperitoneal paclitaxel remains to be defined.Entities:
Mesh：
Substances：
Year: 1997 PMID： 9090476
Source DB: PubMed Journal: Curr Opin Obstet Gynecol ISSN： 1040-872X Impact factor: 1.927